)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
NextCell Pharma
NextCell Pharma (NXTCL) investor relations material
NextCell Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Launched first commercial product, NextCell-Cord RUO, in partnership with FUJIFILM Biosciences, expanding global reach.
Strengthened presence in Asia with new office in Hong Kong and participation in EU-Japan Biotech Business Mission.
Awaiting comprehensive data readout from ProTrans-Young clinical study in type 1 diabetes.
Continued development of NXTCL platform and strategic rebranding of drug candidates.
Financial highlights
Operating income for Q2 2026 was SEK 3.0 million, up from SEK 1.5 million year-over-year.
Net income for Q2 2026 was SEK -11.7 million, compared to SEK -11.2 million in Q2 2025.
Cash and cash equivalents at quarter-end were SEK 21.1 million, down from SEK 46.9 million a year earlier.
Earnings per share for Q2 2026 were SEK -0.09, improved from SEK -0.13 in Q2 2025.
Total cash flow for Q2 2026 was SEK -11.2 million, compared to SEK 24.8 million in Q2 2025.
Outlook and guidance
Focus on commercial execution of the TD1 program and expansion of manufacturing capabilities.
Anticipates further clinical data from ProTrans-Young to support treatment efficacy in type 1 diabetes.
Strategy includes building international partnerships and strengthening clinical and commercial foundations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NextCell Pharma
- Cash position strengthened by share issue despite increased operating loss and lower sales.NXTCL
Q1 2026 - ProTrans clinical progress, international expansion, and stable liquidity highlight the period.NXTCLTransition period
- ProTrans shows durable efficacy in diabetes, with global expansion and new indications ahead.NXTCLLife Science Summit 2025
- Losses narrowed and revenues grew as clinical and operational milestones were reached.NXTCLQ4 2025
- Net loss narrowed year-over-year as funding and partnerships strengthened clinical progress.NXTCLQ3 2025
- ProTrans clinical progress and successful capital raise position NextCell for future growth.NXTCLQ4 2024
- Rights issue oversubscribed, raising SEK 40.1M to fund ProTrans trials and operations.NXTCLQ3 2024
- ProTrans-Young shows strong safety but unclear efficacy after one year; long-term data awaited.NXTCLStudy Result
- ProTrans advances in diabetes, Cellaviva and QVance drive growth, losses narrow.NXTCLQ1 2025
Next NextCell Pharma earnings date
Q3 202626 Nov, 2026
NextCell Pharma
Next NextCell Pharma earnings date
Q3 202626 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage